CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 550 enrolled
Drug / intervention
Mupirocin (Bactroban) 2%; hexachlorophene (pHisoHex) 3% +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00631566
NCT00631566N/ACompleted
CompareCT.gov

Prospective Study on the Incidence, Predictors, and Characteristics of Methicillin-Resistant Staphylococcus Aureus Infections and a Randomized, Double-Blind Study on Decolonization Procedures for Prevention of MRSA Infections Among HIV-Infected Persons

Henry M. Jackson Foundation for the Advancement of Military Medicine·interventional·Posted Mar 7, 2008·Updated Mar 3, 2023

In Brief

A clinical study evaluating Mupirocin (Bactroban) 2%; hexachlorophene (pHisoHex) 3% and Placebo for HIV Infections and Staphylococcal Infections. Completed, enrolled 550 participants across 4 sites.

Detailed Summary

This study will prospectively evaluate the prevalence and incidence (over a two year period) of MRSA colonization and infection among HIV-infected military beneficiaries to determine predictors for the development of MRSA colonization and infection. This study will also investigate the utility of decolonization procedures for clearance of MRSA carriage and prevention of MRSA infections. Finally, the molecular characteristics and the antimicrobial sensitivities of isolates in this population will be determined.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections, Staphylococcal Infections
CountriesUnited States
CollaboratorsInfectious Diseases Clinical Research Program, National Institute of Allergy and Infectious Diseases (NIAID), US Military HIV Research Program

Timeline

N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 7, 2008
Enrollment StartMay 1, 2007
Primary CompletionMay 1, 2017
Study CompletionOct 1, 2017
TodayJul 2, 2026
Enrollment to primary: 10 yearsPosted 18.3 years ago

Interventions

Mupirocin (Bactroban) 2%; hexachlorophene (pHisoHex) 3%drug

BACTROBAN NASAL is a white to off-white ointment that contains 2.15% w/w mupirocin calcium (equivalent to 2.0% pure mupirocin free acid) in a soft white ointment base. The inactive ingredients are paraffin and a mixture of glycerin esters (SOFTISAN 649). pHisoHex, brand of hexachlorophene detergent cleanser, is an antibacterial sudsing emulsion for topical administration. Some randomized patients will receive mupirocin (Bactroban) nasal ointment plus hexachlorophene (pHisoHex) body washes for seven days.

Placebodrug

Some randomized patients will receive a placebo nasal ointment (white petroleum) and a placebo body soap with no antimicrobial activity for seven days.